Prothena reported $-18.49M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 120.06M 19.15M Sep/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Exelixis USD 275.36M 19.96M Sep/2026
Immunic USD -22.78M 753K Jun/2024
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
MacroGenics USD -64.54M 34.34M Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Prothena USD -18.49M 44.46M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026